Serum Midkine Levels in Systemic Lupus Erythematosus

Area of Science:

• Immunology
• Rheumatology
• Biomarker Discovery

Background:

• Midkine (MK) is implicated in inflammation and may inhibit regulatory T cell differentiation.
• Previous research suggests a potential role for MK in autoimmune diseases like SLE, but data in SLE patients is limited.
• The precise role of Midkine in the pathogenesis of Systemic Lupus Erythematosus (SLE) remains largely undefined.

Purpose of the Study:

• To compare serum Midkine (MK) levels between SLE patients and healthy controls.
• To investigate the relationship between serum MK levels and disease activity in SLE patients.
• To explore the potential of MK as a biomarker in SLE.

Main Methods:

• A cross-sectional study involving 90 participants (40 SLE patients, 50 healthy controls).
• SLE diagnosis confirmed using Systemic Lupus International Collaborating Clinics (SLICC) criteria.
• Disease activity assessed with the Mexican Systemic Lupus Erythematosus Disease Activity Index (MEX-SLEDAI).
• Exclusion criteria included malignancy and other systemic diseases; data analyzed using SPSS 22.

Main Results:

• Serum Midkine (MK) levels were significantly higher in SLE patients compared to healthy controls (P < 0.001).
• Elevated MK serum levels showed a significant association with active SLE disease compared to remission (P = 0.018).
• The study identified a statistically significant difference in median serum MK levels between the two groups.

Conclusions:

• Elevated serum Midkine (MK) levels may serve as a potential marker for SLE disease activity.
• Midkine appears to play a role in the underlying pathogenesis of Systemic Lupus Erythematosus (SLE).
• Further research is warranted to elucidate the exact mechanisms of MK in SLE.